Literature DB >> 24339842

DETERMINANTS OF CUTANEOUS INJECTION-RELATED INFECTIONS AMONG INJECTION DRUG USERS AT AN EMERGENCY DEPARTMENT.

Elisa Lloyd-Smith1, Mark Tyndall, Ruth Zhang, Eric Grafstein, Sam Sheps, Evan Wood, Julio Montaner, Thomas Kerr.   

Abstract

INTRODUCTION: Cutaneous injection-related infections (CIRI) are a primary reason injection drug users (IDU) access the emergency department (ED).
METHODOLOGY: Using Cox proportional hazard regression, we examined predictors of ED use for CIRI, stratified by sex, among 1083 supervised injection facility (SIF) users.
RESULTS: Over a four-year period, 289 (27%) visited the ED for CIRI, yielding an incidence density for females of 23.8 (95% confidence interval (CI): 19.3 - 29.0) and males of 19.2 per 100 person-years (95% CI: 16.7 - 22.1). Factors associated with ED use for CIRI among females included residing in the Downtown Eastside (DTES) (adjusted hazard ratio [AHR] = 2.06 [1.13 - 3.78]) and being referred to hospital by SIF nurses (AHR = 4.48 [2.76 - 7.30]). Among males, requiring assistance with injection (AHR = 1.38 [1.01 - 1.90]), being HIV-positive (AHR = 1.85 [1.34 - 2.55]), and being referred to hospital by SIF nurses (AHR = 2.97 [1.93 - 4.57]) were associated with an increased likelihood of an ED visit for CIRI.
CONCLUSION: These results suggest SIF nurses have facilitated referral of hospital treatment for CIRI, highlighting the need for continued development of efficient and collaborative efforts to reduce the burden of CIRI.

Entities:  

Keywords:  abscesses; cellulitis; emergency department; epidemiology; gender; health services; injection drug use

Year:  2012        PMID: 24339842      PMCID: PMC3856908          DOI: 10.2174/1874279301206010005

Source DB:  PubMed          Journal:  Open Infect Dis J


  24 in total

1.  Supervised injecting centres.

Authors:  Nat M J Wright; Charlotte N E Tompkins
Journal:  BMJ       Date:  2004-01-10

2.  High rates of primary care and emergency department use among injection drug users in Vancouver.

Authors:  T Kerr; E Wood; E Grafstein; T Ishida; K Shannon; C Lai; J Montaner; M W Tyndall
Journal:  J Public Health (Oxf)       Date:  2004-11-25       Impact factor: 2.341

3.  Attendance at supervised injecting facilities and use of detoxification services.

Authors:  Evan Wood; Mark W Tyndall; Ruth Zhang; Jo-Anne Stoltz; Calvin Lai; Julio S G Montaner; Thomas Kerr
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

4.  Factors associated with frequent needle exchange program attendance in injection drug users in Vancouver, Canada.

Authors:  C P Archibald; M Ofner; S A Strathdee; D M Patrick; D Sutherland; M L Rekart; M T Schechter; M V O'Shaughnessy
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-02-01

5.  Access and utilization of HIV treatment and services among women sex workers in Vancouver's Downtown Eastside.

Authors:  Kate Shannon; Vicki Bright; Janice Duddy; Mark W Tyndall
Journal:  J Urban Health       Date:  2005-06-08       Impact factor: 3.671

6.  Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy.

Authors:  Michelle Floris-Moore; Yungtai Lo; Robert S Klein; Nancy Budner; Marc N Gourevitch; Galina Moskaleva; Ellie E Schoenbaum
Journal:  J Acquir Immune Defic Syndr       Date:  2003-11-01       Impact factor: 3.731

7.  Predictors of hospitalization for injection drug users seeking care for soft tissue infections.

Authors:  Traci A Takahashi; Amy Baernstein; Ingrid Binswanger; Katharine Bradley; Joseph O Merrill
Journal:  J Gen Intern Med       Date:  2007-03       Impact factor: 5.128

8.  Proposed declassification of disease categories related to sexual orientation in the International Statistical Classification of Diseases and Related Health Problems (ICD-11).

Authors:  Susan D Cochran; Jack Drescher; Eszter Kismödi; Alain Giami; Claudia García-Moreno; Elham Atalla; Adele Marais; Elisabeth Meloni Vieira; Geoffrey M Reed
Journal:  Bull World Health Organ       Date:  2014-06-17       Impact factor: 9.408

9.  Skin and soft tissue infections and vascular disease among drug users, England.

Authors:  Charles Irish; Roy Maxwell; Mark Dancox; Paul Brown; Caroline Trotter; Julia Verne; Mary Shaw
Journal:  Emerg Infect Dis       Date:  2007-10       Impact factor: 6.883

10.  Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study.

Authors:  Elisa Lloyd-Smith; Evan Wood; Ruth Zhang; Mark W Tyndall; Julio S G Montaner; Thomas Kerr
Journal:  BMC Public Health       Date:  2008-12-09       Impact factor: 3.295

View more
  5 in total

Review 1.  Leaving the Hospital Against Medical Advice Among People Who Use Illicit Drugs: A Systematic Review.

Authors:  Lianping Ti; Lianlian Ti
Journal:  Am J Public Health       Date:  2015-10-15       Impact factor: 9.308

Review 2.  Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review.

Authors:  Mary Clare Kennedy; Mohammad Karamouzian; Thomas Kerr
Journal:  Curr HIV/AIDS Rep       Date:  2017-10       Impact factor: 5.071

3.  Use of on-site detoxification services co-located with a supervised injection facility.

Authors:  Andrew Gaddis; Mary Clare Kennedy; Ekaterina Nosova; M-J Milloy; Kanna Hayashi; Evan Wood; Thomas Kerr
Journal:  J Subst Abuse Treat       Date:  2017-08-08

4.  Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study.

Authors:  Mary Clare Kennedy; Kanna Hayashi; M-J Milloy; Evan Wood; Thomas Kerr
Journal:  PLoS Med       Date:  2019-11-26       Impact factor: 11.069

5.  Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain.

Authors:  Jorge Valencia; Jesús Troya; Jeffrey V Lazarus; Guillermo Cuevas; Alejandro Alvaro-Meca; Juan Torres; Carlos Gardeta; David Lozano; Santiago Moreno; Pablo Ryan
Journal:  Open Forum Infect Dis       Date:  2021-05-25       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.